AUSTEDO was studied in a diverse patient population1,2

Results across elderly patients (aged ≥65 years) and younger patients (aged 21-64 years)2,3

  • Elderly and younger patients with TD (ages 21-81) included in pivotal studies
  • Consistent treatment results across elderly and younger patients in open-label extension study
    • Largest elderly population of any TD clinical study (n=78)
See long-term data for elderly and younger patients

Patients had a range of psychiatric and comorbid conditions2

  • Gastrointestinal disorders
  • Cardiovascular disorders
  • Metabolism/nutritional disorders, including diabetes
  • Lipid disorders
  • General liver disorders*

Patients were taking concomitant medications, including those metabolized by CYP3A4/5 and CYP2D61,2,4

  • Antidepressants at baseline: 54% of patients
  • Antipsychotics
  • Atypical: 62% of patients
  • Typical or combination: 14% of patients
  • None at baseline: 24% of patients

*Patients with hepatic impairment were excluded from studies.2,4

REFERENCES: 1. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 3. AUSTEDO XR® (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 4. PubChem Compound Database. National Center for Biotechnology Information. Accessed March 26, 2025. https://pubchem.ncbi.nlm.nih.gov